Savara Inc. (SVRA)
NASDAQ: SVRA · Real-Time Price · USD
3.135
+0.005 (0.16%)
At close: May 20, 2025, 4:00 PM
3.130
-0.005 (-0.16%)
After-hours: May 20, 2025, 5:06 PM EDT
Savara Employees
Savara had 59 employees as of December 31, 2024. The number of employees increased by 22 or 59.46% compared to the previous year.
Employees
59
Change (1Y)
22
Growth (1Y)
59.46%
Revenue / Employee
n/a
Profits / Employee
-$1,731,763
Market Cap
660.51M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
SVRA News
- 2 days ago - Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at American Thoracic Society Conference (ATS) 2025 - Business Wire
- 7 days ago - Savara Reports First Quarter 2025 Financial Results and Provides a Business Update - Business Wire
- 8 days ago - Savara Announces Participation in the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference - Business Wire
- 19 days ago - Savara Announces Participation in the Upcoming Citizens Life Sciences Conference - Business Wire
- 4 weeks ago - Savara: Make-It-Or-Break-It Molbreevi BLA Filing - Seeking Alpha
- 5 weeks ago - Savara Announces New Employment Inducement Grant - Business Wire
- 6 weeks ago - Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences - Business Wire
- 7 weeks ago - Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update - Business Wire